Lifeward Ltd.

Good morning and welcome to the third quarter 2025 LifeWord earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. please note this event is being recorded. I would now like to turn the conference over to Almog Adar, CFO of LifeWord. Please go ahead.

Thank you, Operator, and thanks to everyone who has joined us on the call today. My name is Almog Adar. I'm LifeWord's Chief Financial Officer, and with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, LifeWord issued a press release detailing the financial results for the third quarter, which ended September 30, 2025. I would like to ask you to review the full text of our forward-looking statement from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filing with the SEC. And with that, I will turn the call Well, this is Mark.

Thank you, Amag. Good morning, everyone, and thank you for your time today. Since joining LifeWord in June, I've completed a sober and comprehensive assessment of the business, starting with our strategic direction down to our commercial model and operations. What I've found is a company with innovative, powerful technology, deep clinical knowledge, and a mission that matters. Also, a company that needs sharper focus, stronger discipline, and rebuilt foundation to unlock its potential. Over the past few months, we've taken meaningful steps to rebuild those fundamentals. We have simplified how we operate, strengthened the processes that matter most to patients, payers, and providers, and begun reshaping our go-to-market approach around the global access, distribution scalability, and data-driven commercial model. The progress we've demonstrated this quarter is encouraging early sign that this work is taking hold. We delivered another record quarter for rewalk placements for Medicare beneficiaries. This is our second consecutive record since CMS established their fee schedule in April of 2024. We implemented meaningful operational efficiencies, manifesting in a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared with last year. We also expanded patient access, including receiving our first Medicare Advantage commercial revenue for our rewalk seven personal exoskeletons. Now, with our CE mark approval, we have expanded our access to the European market, which represents roughly about 40% of our global addressable exoskeleton opportunity. These results are demonstrating that LifeWord is becoming a more focused, more efficient, and more patient-centered company. Earlier today, alongside our earnings release, we also announced the completion of a $3 million loan with Oramed. This capital enhances our near-term liquidity and supports ongoing execution of our transformation plans. We are still early in a multi-quarter rebuild. Understand there is more work ahead. And I have confidence in the commitment and the dedication of our teams across our company to complete this transformation. We are highly encouraged that soon after implementing these measures, we are already seeing real momentum and a clear direction. We are rebuilding the fundamentals and positioning LifeWord to serve more people, scale more efficiently, and create durable long-term value. With that, I'll turn the call over to our CFO, Amogh, to review the financial results from this quarter.